CMV, EBV AND PARVOVIRUS STATUS IN PATIENTS WITH TYPE 1 DIABETES MELLITUS AWAITING ISLET CELL TRANSPLANTATION

2004 ◽  
Vol 78 ◽  
pp. 354-355
Author(s):  
M M. Hafiz ◽  
D A. Baidal ◽  
R Poggioli ◽  
T Froud ◽  
J V. Ferreira ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cell Transplantation ◽  
Islet Cell ◽  
Islet Cell Transplantation

scholarly journals Ambulatory intravenous insulin and islet cell transplantation to treat severe type III insulin hypersensitivity in a patient with type 1 diabetes mellitus

2020 ◽  
Vol 8 (12) ◽  
pp. 2759-2762
Author(s):  
Brigette Clarke ◽  
Tom Loudovaris ◽  
Toni Radford ◽  
Chris Drogemuller ◽  
Patrick Toby Coates ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cell Transplantation ◽  
Islet Cell ◽  
Islet Cell Transplantation ◽  
Intravenous Insulin ◽  
Severe Type ◽  
Insulin Hypersensitivity

scholarly journals Evaluation of Metabolic Control Using a Continuous Subcutaneous Glucose Monitoring System in Patients with Type 1 Diabetes Mellitus who Achieved Insulin Independence after Islet Cell Transplantation

2005 ◽  
Vol 14 (2-3) ◽  
pp. 77-84 ◽  
Author(s):  
Milene C. Geiger ◽  
Jacqueline V. Ferreira ◽  
Muhammad M. Hafiz ◽  
Tatiana Froud ◽  
David A. Baidal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Metabolic Control ◽  
Cell Transplantation ◽  
Monitoring System ◽  
Islet Cell ◽  
Glucose Monitoring ◽  
Islet Cell Transplantation

This study evaluated the Medtronic MiniMed Continuous Glucose Monitoring System (CGMS) in patients with type 1 diabetes mellitus who underwent successful islet cell transplantation (ICT). The results are compared to standardized self-monitoring (SMBG) of hyperglycemia and mean amplitude of glycemic excursions (MAGE). We studied 19 patients (mean age 40.0 ± 6.7 years) in three groups: six patients post-ICT, seven patients awaiting ICT, and six normal volunteers (controls). Continuous glucose monitoring post-ICT showed remarkable glucose stability compared with patients awaiting ICT. The CGMS group showed modestly higher glucoses (mean 111.5 mg/dl) compared with controls (88 mg/dl). Postprandial glucoses in ICT recipients rarely exceeded 180 mg/dl and were similar to controls. There was no difference in asymptomatic hypoglycemia between control and post-ICT groups. However, a higher incidence of hypoglycemia was observed in patients awaiting ICT. HbA1c and MAGE pre- and post-ICT were 8.3 ± 0.9% and 6 ± 0.3% (p < 0.001) and 109 ± 34 and 41 ± 11 (p < 0.001), respectively. No complications were associated with CGMS. This study suggests ICT significantly improves metabolic control and rate of hypoglycemia when compared with controls and patients awaiting ICT. Similar improvement in metabolic control was observed with SMBG, HbA1c, and MAGE. Although CGMS was not demonstrated to be a superior tool for routine assessment in ICT, it is very helpful in special clinical situations.

Immunosuppression and Procedure-Related Complications in 26 Patients with Type 1 Diabetes Mellitus Receiving Allogeneic Islet Cell Transplantation

2005 ◽  
Vol 80 (12) ◽  
pp. 1718-1728 ◽  
Author(s):  
Muhammad M. Hafiz ◽  
Raquel N. Faradji ◽  
Tatiana Froud ◽  
Antonello Pileggi ◽  
David A. Baidal ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cell Transplantation ◽  
Islet Cell ◽  
Islet Cell Transplantation

Percutaneous Transhepatic Pancreatic Islet Cell Transplantation in Type 1 Diabetes Mellitus: Radiologic Aspects

Radiology ◽  
2003 ◽  
Vol 229 (1) ◽  
pp. 165-170 ◽  
Author(s):  
Richard J. T. Owen ◽  
Edmond A. Ryan ◽  
Kevin O’Kelly ◽  
Jonathan R. T. Lakey ◽  
Mairin C. McCarthy ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 1 Diabetes ◽  
Type 1 Diabetes Mellitus ◽  
Cell Transplantation ◽  
Pancreatic Islet ◽  
Islet Cell ◽  
Islet Cell Transplantation ◽  
Pancreatic Islet Cell
Sign in / Sign up

Export Citation Format

Share Document